ReviewKidney international reports2021
Sarcopenia and Frailty: Challenges in Mainstream Nephrology Practice.
Review in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Effects of exercise interventions on inflammatory biomarker levels in older adults with frailty and/or sarcopenia: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Exercise interventions and serum IGF-1 levels in older adults with frailty and/or sarcopenia: a systematic review and meta analysis.Frontiers in public health · 2025Pooled it
- Handgrip strength and all-cause mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis of cohort studies.International urology and nephrology · 2023Pooled it
- Prevalence of physical frailty and impact on survival in patients with chronic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2023Pooled it
- Pooled it
- [The Nephrogeriatrics Research Network-achieving more through interdisciplinary approaches].Innere Medizin (Heidelberg, Germany) · 2026Review
- Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia · 2026Article
- Article
- Muscle Matters: Poor Muscle Quality Increases Mortality Risk in Early CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Article
- The effects of resistance training on myostatin in older adults with frailty and/or sarcopenia: a systematic review and meta analysis.BMC sports science, medicine & rehabilitation · 2026Article
- Association between temporal muscle morphology based on MRI and muscle mass and strength in healthy young adults: a cross-sectional study.BMC musculoskeletal disorders · 2026Article
- Proximal Tubule-Specific Genetic Deficiency of PPARα Worsens Systemic Lipid and Glucose Metabolism During Fasting.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Development of a risk prediction model for dialysis access steal syndrome: exploring the interaction and modifying role of BMI.Frontiers in public health · 2026Article
- Impact of Dry Mouth and Factors Associated with Sarcopenia on Oral Health-Related Quality of Life in Peritoneal Dialysis Patients.European journal of dentistry · 2025Article
- When the Heart, Kidneys, and Body Waste Away: A Review of Cachexia in Cardiorenal Syndrome.Current heart failure reports · 2025Review
- Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population.Journal of cachexia, sarcopenia and muscle · 2025Article
- Review of Blood Pressure Control in Vulnerable Older Adults: The Role of Frailty and Sarcopenia.Journal of vascular diseases · 2025Article
- Myosteatosis: an underrecognized risk factor for mortality in non-dialysis chronic kidney disease patients.Journal of nephrology · 2024Article
- Effect of low muscle mass on total mortality related to metabolic disease in chronic kidney disease patients.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia and frailty are prevalent in the chronic kidney disease (CKD) population. Sarcopenia is characterised by the loss of muscle mass and function, while frailty is defined as a multi-system impairment associated with increased vulnerability to stressors. There is substantial overlap between the 2 conditions, particularly with regards to physical aspects: low grip strength, gait speed and low muscle mass. Both sarcopenia and frailty have been associated with a wide range of adverse health outcomes. Although there is no recommended pharmacological treatment as yet, it is widely accepted that exercise training and nutritional supplementation are the key interventions to maintain skeletal muscle mass and strength. This review aims to present a comprehensive overview of sarcopenia and frailty in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.